Media Advisory - Oncolytics Biotech® Inc. Announces Participation in Upcoming Conferences

CALGARY, Sept. 9, 2013 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at Baird's 2013 Healthcare Conference on Tuesday September 10th, 2013 at 8:30 a.m. ET. The conference will take place on September 10th and 11th in New York, NY at the New York Palace.

A live audio link to the Baird webcast presentation will be available at:

Dr. Thompson is also presenting at the Stifel 2013 Healthcare Conference on Wednesday September 11, 2013 at 1:30 p.m. ET. The conference is taking place from September 11th to 13th in Boston, MA at the Four Seasons Hotel.

A live audio link to the Stifel webcast presentation will be available at:

Dr. Thompson is also presenting at the WDM 1st Global Life Sciences Conference on Monday, September 16, 2013 at 10:30 a.m. CEST. The conference is taking place on September 16th and 17th in Warsaw, Poland.

A live audio link to the WDM webcast presentation will be available at:

Links to the presentations will also be available on the company's website at   It is recommended that listeners log on 10 minutes in advance of a live presentation to register and download any necessary software. Links to the audio replays will be accessible following the presentations on the Oncolytics website.

About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.  Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN®, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit:

The presentation and webcast times are subject to change. This release and the presentation related thereto contain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control and which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.

SOURCE Oncolytics Biotech Inc.